Reason for referral: provide patient education on management of hypoglycemia and glucose monitor

Size: px
Start display at page:

Download "Reason for referral: provide patient education on management of hypoglycemia and glucose monitor"

Transcription

1 Meet Robin Sawyer (otherwise known as PT 1): Let s Create a Care Plan! Reason for referral: provide patient education on management of hypoglycemia and glucose monitor History of present illness: yo lawyer, 6 2, 210 lbs (BMI 27), diagnosed with type 2 diabetes 6 yrs ago. His GP recently started long acting insulin glargine (Lantus ) once daily at bedtime. Robin was instructed to check his blood glucose more often. With his busy lifestyle and work schedule, Robin doesn t feel he ll be able to do it. He is unsure of how often and what times of day. He finds it difficult to have a meter with him at all times (home, office, court, lunch meetings). Sometimes, he doesn t know if the strips are expired and if they can be used past the expiration date. He is worried he experienced a couple episodes of low blood sugar (based on dizziness) in last week, yet he could not verify. He wants to know if testing all the time is necessary and what the latest research says. Past Medical History: Dyslipidemia HTN DM No history of CVD Tonsillectomy at age 2 7 Leg fracture, age Medication Allergies: NKDA Medication History: Indication Drug Name Directions Adherence (Y/N) Notes/Comments Diabetes Metformin 1000 mg BID (AM and supper) Y, except noon Taken x 6 years 500 mg at noon dose often missed Diabetes Gliclazide 80 mg BID (AM and supper) Y Taken x 5 years Diabetes Insulin glargine (Lantus ) 10 units qhs Y Started 1 month ago; tolerating injections Hyperlipidemia Atorvastatin 10 mg QHS Y Taken X 2 years Hypertension Ramipril 10 mg QAM Y Started 3 years ago No OTC use (and specifically does not take aspirin) Receives yearly influenza vaccine Organizes medications himself; does not use dosette or blister pack Generally remembers to take his medications Is not bothered that he takes chronic medications; generally feels well except for some recent dizzy spells Social History: (+) smoking: 5 6 cigarettes/day x past year (1ppd x 20 years prior to this), cigar on the weekend at the country club. Tried quitting in the past but the stress of the job makes it difficult. Diet: eats breakfast and supper routinely; sometimes misses lunch due to busy schedule. Tries to eat DM diet. EtOh: nil Occupation: lawyer Married, 2 teenage children Family History: (+) diabetes maternal grandmother, father Strong family history of heart disease (Dad, MI, age 50; Mom, stroke, age 60)

2 Review of Systems CNS: occ. light headedness and dizziness which he thinks may be associated with low FPG from skipping meals, but does not check with meter. No HA reported. CVS: BP (MD office last week) 128/80, HR 70 bpm; does not use home BP monitor Resp: no concerns Abdo: mild central obesity, lost 30 lbs in last 6 yrs since diagnosed with DM. Normal BM; no N/V General: overall, has increased stress related to his occupation. Investigations Labs (taken last week as per physician request) Parameter Actual Normal Range Na 142 mmol/l mmol/l K 4.1 mmol/l mmol/l Scr 102 umol/l umol/l BUN 4.3 umol/l LDL 1.66 mmo/l Treatment Goals HDL 1.13 mmo/l T CHol 4.09 mmo/l Trig 2.87 mmo/l Total:HDL 3.6 ALT 15 U/L < 50 U/L AST ALP T Bili A1C 7.9 % % FPG 7.7 mmol/l mmol/l Hgb 136 g/l g/l WBC 5.2 x 10 9 /L 4 11 x 10 9 /L Urine Microalbumin/Creatinine ratio 0.1 mg/mmol < 2.0 mg/mmol For all patients, a primary target is a reduction of greater than or equal to 50% in the LDL cholesterol value. For patients classified as high or moderate risk, the primary target is a reduction of greater than or equal to 50% in the LDL cholesterol value or a LDL of < 2.0 mmol/l.

3 PHARMACY CARE PLAN WORKSHEET Robin Sawyer MEDICAL CONDITION AND/OR DRPs DM 1. Requires education about blood glucose monitoring (BGM) to use insulin safely 2. Appears to be experiencing hypoglycemia (dizziness) when meals skipped 3. A1C 7.9 which is suboptimal for him 4. Lifestyle and CV risk factors given he has DM see below GOALS OF THERAPY ALTERNATIVES RECOMMENDATIONS/ PLAN 1. Educate on importance of glucose monitoring for using insulin safely, and link between insulin use and potential for hypoglycemia. 2. Determine if dizziness caused by hypoglycemia. 3. Goal A1C<7: need to review BG pattern to see if patient is meeting ac and pc BG targets; need to minimize hypoglycemia while achieving this. 1. Education on glucose monitoring; No alternatives stress importance of BGM while on insulin and discuss strategies to implement 2. No alternatives; need to definitively determine if hypoglycemia is occurring *Consider hypotension as alternate explanation for dizziness. 3. Goal A1C while minimizing dizziness a. Based on ac and pc BG and A1C, may need to optimize insulin/oral regimen 1. Encourage BGM (qid initially including ac and pc lunch) to determine if low BG are likely causing dizzy spells. Use journal to track. Provided info on strips and expiry. New strips provided. 2. Suggested ways today to treat hypoglycemia if present (based on BGM) a. Sugar candies b. Eating regular meals 3. Sold additional (small) BGM for use in office (he didn t realize small monitors available) MONITORING PARAMETERS Short term: # of dizzy spells, when they occur, corresponding BGM data to confirm if dizziness is related to low BG Long term: address achieving A1C goal and modification/intensification of therapy to achieve this. Review BG levels once using a BGM. Re check A1C in 3 months (insulin newly started). CV Risk Assessment (Framingham 2008 version): high risk for primary prevention based on age <45 + DM and 3 other risk factors (HTN, smoking, positive family history) Dyslipidemia 1. LDL<2mmol/L: goal achieved None required goal met. (LDL Tolerability of atorvastatin mmol/l) 3. Adherence HTN Last BP reading 128/80 1. Goal < 130/80 (DM) 2. Implement Home BP Monitoring (HBPM) 3. Tolerability of ramipril 4. Adherence None required at this time goal met. (128/80) Ensure home BPs are controlled. 1. Continue atorvastatin 10 mg daily as prescribed. 2. Tolerating well (specifically no myopathy), ALT normal 1. Continue ramipril 10 mg daily 2. Tolerating ramipril, K+ 4.1, Scr 102 (unchanged from 1 yr ago), ACR N 3. Recommend purchasing home BP monitor in future 1. Alert us if concerns arise 2. Ensure LDL<2 mmol/l maintained annually 3. Adherence Deferred; patient will try HBPM in future once DM better controlled FOLLOW UP Short term: How: phone or in person depending on Robin s schedule When: 1 2 weeks Long term plan will be determined based on data gathered for current issue. Who: he will call if problem How: phone/person When: every 3 6 months for adherence, annually for lipid profile How: next inperson visit When: 1 4 months ASA indication for use? To reduce CV events, namely MI, while minimizing risk of bleeding 1. Aspirin mg daily PRO: will reduce total CV events by 12%, and MI by 23%. Given high risk status, he may benefit IF his risk of GI bleeding is low. Would need to explore next visit CON: No evidence in DM currently that dictates use of ASA without evidence of CVD, overall event rate low based on age, bleeding risk increased (GI and ICH) 1. Defer; will discuss with Robin next time we meet. Need to discuss bleeding history. Interest in using ASA after discussing benefits/risks with him. How: next inperson visit When: 1 4 months

4 Lifestyle changes 1. Smoking 2. Diet/weight 3. Exercise regimen 1. Assess readiness to quit smoking 2. Review diet/eating pattern and reinforce importance of losing weight (or not gaining weight) 3. Implement 30 minutes/day 3x/week (Robin feels this is doable) 1. Assessment/discussion of readiness versus no discussion depending on time frame 2. Suggest ways to incorporate eating through day to minimize hypoglycemia; promote DM diet 3. Discussed types of activities he likes: walking, tennis, biking 1. Not interested in quitting at this time; will consider in future. 2. Will try and have snacks/preprepared meals on hand for convenience 3. Will exercise starting 3x/wk 1. Smoking readiness toquit; discuss in future 2. Success of dietary changes 3. Success of exercise pattern How: next visit When: 1 2 months; focus on smoking cessation as he would like to achieve this in future

5 Example of Initial Consult Note Robin Sawyer (otherwise known as PT 1) DATA Reason for Referral: provide patient education on management of dizziness (?hypoglycemia) and home glucose monitor HPI: yo lawyer, 6 2, 210 lbs (BMI 27), diagnosed with type 2 diabetes x 6 yrs GP recently started long acting insulin glargine (Lantus ) HS. Instructed to check his blood glucose more often. With his busy lifestyle and work not been able to do it. He is unsure of how often and what times of day. He finds it difficult to have a glucometer with him at all times (home, office, court, lunch meetings). Also concerned strips are expired and wants to know if they can be used past expiration date Worried he experienced a couple episodes of low blood sugar (based on dizziness) in last week in early afternoon after skipping lunch, yet he could not verify. Wants to know if testing all the time is necessary and what the latest research says. Relevant Past Medical History: Dyslipidemia, HTN, No history of CVD Medication Allergies: NKDA Medication History: Indication Drug Name Directions Adherence (Y/N) Notes/Comments Diabetes Metformin 1000 mg BID (AM and supper) Y, except noon dose Taken x 6 years 500 mg at noon often missed Diabetes Gliclazide 80 mg BID (AM and supper) Y Taken x 5 years Diabetes Lantus insulin 10 units qhs Y Started 1 month ago; tolerating injections Hyperlipidemia Atorvastatin 10 mg QHS Y Taken X 2 years Hypertension Ramipril 10 mg QAM Y Started 3 years ago No OTC use and does not take daily aspirin; receives yearly influenza vaccine Med Management: organizes medications himself; does not use dosette or blister pack Social History: (+) smoking: 5 6 cigarettes/day x past year (1ppd x 20 years prior to this), cigar on the weekend at the country club. Tried quitting in the past but the stress of the job makes it difficult. Not interested in quitting at this time. Diet: eats breakfast and supper routinely; sometimes misses lunch due to busy schedule. Tries to eat DM diet. Family History: (+) DM maternal grandmother, father (+) family history CAD (Dad, MI, age 50; Mom, stroke, age 60) Review of Systems CNS: occ. light headedness and dizziness which he thinks may be associated with low FPG from skipping meals, but does not check with meter. No HA reported. CVS: BP (MD office last week) 128/80, HR 70 bpm; does not use home BP monitor Abdo: mild central obesity, lost 30 lbs in last 6 yrs since diagnosed with DM. Normal BM; no N/V

6 General: overall, has increased stress related to his occupation. Investigations Labs (taken last week as per physician request) Parameter Actual Normal Range K 4.1 mmol/l mmol/l Scr 102 umol/l umol/l LDL 1.66 mmo/l < 2 mmol/l ALT 15 U/L < 50 U/L A1C 7.9 % % FPG 7.7 mmol/l mmol/l Urine Microalbumin/Creatinine ratio 0.1 mg/mmol < 2.0 mg/mmol ASSESSMENT/PLAN 1. Education on proper blood glucose monitoring and its importance provided, especially when using insulin and experiencing dizziness. a. Agrees to purchasing new, small glucometer for use in the office b. Will record his FBG readings for review by pharmacist in 2 weeks. c. Important to check the glucose 3 4 times a day when insulin regimen is new, especially during episodes of dizziness and if insulin dose changes. If can only check bid, best times would be ac breakfast and hs. 2.?Hypoglycemia; obtain FBG readings periodically as well as during dizzy spells to verify if this is actual cause a. Avoid skipping lunch and try to have 6 small meals spread throughout day. b. Carry dextrose tablets or hard candies and use if feeling dizzy and FBG is low (less than 3.5 mmol/l) 3. Optimize A1C to less than 7 over next 3 6 months; A1C currently 7.9 a. Assess drug options after viewing FBG records b. Insulin dose may need to be changed; consider more intensive regimen c. Repeat A1C when appropriate in future 4. CV Risk Assessment high risk based on Framingham and UKPDS. Needs aggressive control of modifiable risk factors. a. Smoking cessation: defer. Aware of options to support him in quitting. b. Weight loss encouraged; goal BMI<25. Referral to dietician made. c. BP: goal less than 130/80. Suggest HBPM for use in future to ensure goal maintained. Follow Scr as elevated, but not different from baseline 1 year ago. K+ normal. ACR normal. d. LDL goal less than 2mmol/L; no change to atorvastatin as goal of less than 2 mmol/l achieved, ALT normal, tolerating atorvastatin well. e. Consider ASA therapy in future. FOLLOW UP: 1 2 weeks for reviewing FBG records and # dizzy spells. Will optimize his DM management then. Consider discussion of HBPM, smoking cessation and ASA.

7 Example Short Documentation for INTERNAL PHARMACY USE DATA yo with DMII, started on insulin glargine hs 1 month ago. Concerned about dizziness (?hypoglycemia) that occurs after skipping lunch. Also wants to know about use of home glucose monitor. HPI: Instructed to check blood glucose more often; with busy lifestyle, not happening. Unsure of how often and when. Difficult to have a glucometer with him at all times (home, office, court, lunch meetings). Relevant PMHx: Dyslipidemia, HTN, No Hx of CVD Medications (NKDA): metformin 1000 mg bid mg lunch, gliclazide 80 mg bid, insulin glargine 10 units hs, atorvastatin 10 mg daily, ramipril 10 mg qam. 100% adherent with all except noon metformin (occ. misses), No OTC use. No ASA use. Tolerates all meds. Cardiac Risk Factors: HTN (BP 128/80), DM, dyslipidemia, (+) smoking (5 6 cigarettes/day x past year, not interested in quitting at this time), +FHx CAD, Diet: sometimes misses lunch, lost 30 lbs in last year. Relevant Labs: K+ 4.1, Scr 102 (similar to Scr 1 year ago), LDL 1.66, ALT 15, A1C 7.9 ASSESSMENT/PLAN 1. Education on proper blood glucose monitoring and its importance provided, especially when using insulin and experiencing dizziness. a. Buys new monitor for use in the office, will record his FBG readings, important to check the glucose tid qid, (both ac and pc meals) esp during episodes of dizziness and if insulin dose changes. If only check bid, try ac breakfast and hs. 2.?Hypoglycemia; obtain FBG readings during dizzy spells to verify if this is actual cause a. Avoid skipping lunch and carry/use dextrose tablets/hard candies if feeling dizzy and FBG low (less than 3.5 mmol/l) 3. Goal A1C to less than 7 over next 3 6 months; Repeat A1C when appropriate 4. CV Risk Assessment high risk based on Framingham and UKPDS. Control modifiable risk factors. a. Smoking cessation: deferred b. Weight loss encouraged; goal BMI less than 25. Referral to dietician made. c. BP: goal less than 130/80. Suggest HBPM for use in future. Follow elevated Scr. K+ normal. d. LDL goal less than 2mmol/L achieved F/U: 1 2 weeks for reviewing FBG records and # dizzy spells. Optimize DM management then. Consider HBPM, smoking cessation and ASA.

Case Studies in T2DM A Comprehensive Management Approach

Case Studies in T2DM A Comprehensive Management Approach Case Studies in T2DM A Comprehensive Management Approach John E. Anderson, MD The Frist Clinic Nashville, TN 43 yo Latina woman with 5 yrs T2DM. Originally diagnosed with PCOS and IGT by GYN at 32 yo.

More information

Complete this CE activity online at ProCE.com/InsulinPart2

Complete this CE activity online at ProCE.com/InsulinPart2 Complete this CE activity online at ProCE.com/InsulinPart2 Case 1: A 67 year old male with T2DM History and Presentation John is a 67 year old retiree who has been visiting your pharmacy/clinic for over

More information

Doctor s Instructions Patient: Mr Abdul Shareef Age: 40. Last Consultation Dr Mitchell 2 weeks ago

Doctor s Instructions Patient: Mr Abdul Shareef Age: 40. Last Consultation Dr Mitchell 2 weeks ago Doctor s Instructions Patient: Mr Abdul Shareef Age: 40 Last Consultation Dr Mitchell 2 weeks ago Telephone Triage: Patient just wants a routine blood test as FH of diabetes. Plan: Fasting blood test,

More information

Application of the Diabetes Algorithm to a Patient

Application of the Diabetes Algorithm to a Patient Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent

More information

VS: BP 165/90, P 98, RR 18, T 37 C; waist circ 38 in, Wt 240 lbs (109 kg), Ht 5'8''

VS: BP 165/90, P 98, RR 18, T 37 C; waist circ 38 in, Wt 240 lbs (109 kg), Ht 5'8'' IMC Didactic Case-Diabetes Mellitus Chief Complaint "I was recently diagnosed with diabetes and would like to have my blood sugar tested. I think that my blood sugar is running low because I have the shakes

More information

RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES

RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES Risk Factors or Complications Glycemic Control Fasting & Capillary Plasma Glucose Anti-platelet

More information

Patient is a 60 YO MALE seen in clinic for diabetes management follow-up. Allergies/ADEs: FLUNISOLIDE, PRIMIDONE, ALEVE CAPLET, CARBAMAZEPINE

Patient is a 60 YO MALE seen in clinic for diabetes management follow-up. Allergies/ADEs: FLUNISOLIDE, PRIMIDONE, ALEVE CAPLET, CARBAMAZEPINE Patient is a 60 YO MALE seen in clinic for diabetes management follow-up. Allergies/ADEs: FLUNISOLIDE, PRIMIDONE, ALEVE CAPLET, CARBAMAZEPINE Dx/Hx: uncontrolled DM and HTN Lifestyle: Patient usually sleeps

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

Case study for CME Diabetes up-to-date management

Case study for CME Diabetes up-to-date management Case study for CME Diabetes up-to-date management Dr Ole Schmiedel, MRCP MD FRACP Physician and Endocrinologist Service Clinical Director Auckland Diabetes Centre GP referral to Auckland Diabetes Centre

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

Learning Objectives

Learning Objectives Learning Objectives Assess the key findings of the McMaster meal replacement therapy (MRT) study Identify patients with T2DM who are candidates for MRT Develop a plan to implement partial MRT into a patient

More information

Patient Case Mrs X Provided compliments of Mary Gunther, BScPharm, ACPR

Patient Case Mrs X Provided compliments of Mary Gunther, BScPharm, ACPR Patient Case Mrs X Provided compliments of Mary Gunther, BScPharm, ACPR ID: Mrs X is a female in her mid sixties admitted for a CHF exacerbation CC: 1. 2 week history of increasing weakness, weight gain,

More information

Record-Keeping Charts

Record-Keeping Charts In this appendix, we have provided some useful charts for you so you can record information that s important to manage your diabetes. Use these charts to keep track of the information not only for yourself,

More information

A Practical Approach to the Use of Diabetes Medications

A Practical Approach to the Use of Diabetes Medications A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE

More information

Type 2 Diabetes Performance Improvement Initiative: Chart Reviews. Lara Zisblatt Boston University School of Medicine Boston, MA

Type 2 Diabetes Performance Improvement Initiative: Chart Reviews. Lara Zisblatt Boston University School of Medicine Boston, MA Type 2 Diabetes Performance Improvement Initiative: Chart Reviews Lara Zisblatt Boston University School of Medicine Boston, MA Participants in the Program 487 people registered 217 people started the

More information

Participants in the Program

Participants in the Program Type 2 Diabetes Performance Improvement Initiative: Chart Reviews Lara Zisblatt Boston University School of Medicine Boston, MA Participants in the Program 487 people registered 217 people started the

More information

Treat-to-Target Tools

Treat-to-Target Tools TEAMcare Care Manager Primary Care Provider Treat to Target Discussion Tool for Treatment Enhancement Activation and Motivation (TEAM) Depression, Diabetes and Coronary Heart Disease (CHD) Intervention

More information

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity

More information

TEAMcare Treat-to-Target Tools

TEAMcare Treat-to-Target Tools TEAMcare Treat-to-Target Tools The TEAMcare Treatment Discussion Tool (treatment protocol) Nurse Case Manager (NCM)-MD Treat-to-Target Discussion Tool for Treatment Enhancement Activation and Motivation

More information

The Metabolic Syndrome: Is It A Valid Concept? YES

The Metabolic Syndrome: Is It A Valid Concept? YES The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

More information

CASE STUDY #3 - NUT 116AL Diabetes Mellitus DUE Monday 12/9/13 (by 1:00pm in Meyer 3241)

CASE STUDY #3 - NUT 116AL Diabetes Mellitus DUE Monday 12/9/13 (by 1:00pm in Meyer 3241) Last Name Reagan First Name Jason Section 2_ CASE STUDY #3 - NUT 116AL Diabetes Mellitus DUE Monday 12/9/13 (by 1:00pm in Meyer 3241) Patricia C. is a 30 yo Asian American woman with T1DM. She was diagnosed

More information

American Academy of Insurance Medicine

American Academy of Insurance Medicine American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker

More information

A Process for Performing Medication Assessments

A Process for Performing Medication Assessments A Process for Performing Medication Assessments Derek Jorgenson, BSP, PharmD, FCSHP College of Pharmacy and Nutrition University of Saskatchewan Objectives 1. Learn an overview of a medication assessment

More information

Advanced Pharmacology Diabetes Homework

Advanced Pharmacology Diabetes Homework Advanced Pharmacology Diabetes Homework Points: 25 Comments: Name: Tracy Hill WU ID #: 20015608 E-mail: tracy.hill@washburn.edu _TH I hereby certify that the work submitted is my own, and that I have not

More information

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Clinical Cases in Diabetes Management. Joseph Cook D.O. Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians

More information

CASE STUDY Diabetes Mellitus FH: PMH: Social Hx PE: Labs: Rx: CAM: Dx: Plan:

CASE STUDY Diabetes Mellitus FH: PMH: Social Hx PE: Labs: Rx: CAM: Dx: Plan: CASE STUDY Diabetes Mellitus Patricia C. is a 30 yo Asian American woman with T1DM. She was diagnosed at age 13. Her insulin regimen is 50 units of insulin (Glargine) every evening and 3 units of Lispro

More information

Primary Care Patient Case Example

Primary Care Patient Case Example Primary Care Patient Case Example Chief Complaint (CC): K.G. presents to your clinic for a follow-up. You work in an interprofessional clinic with physicians. He has no complaints today. History of the

More information

Learning Objectives. Outline 4/3/2018. Treatment Strategies to Maximize the Value of Diabetes Medications

Learning Objectives. Outline 4/3/2018. Treatment Strategies to Maximize the Value of Diabetes Medications Treatment Strategies to Maximize the Value of Diabetes Medications Presenters: Jennifer Toy, PharmD, BCACP and Crystal Zhou, PharmD, APh AHSCP, BCACP Learning Objectives 1. Discuss which patients may benefit

More information

Date of Birth. Black/African American. What is your occupation? Retired? Yes No

Date of Birth. Black/African American. What is your occupation? Retired? Yes No Health Risk Assessment Today s Date: Name Date of Birth GENERAL INFORMATION What is your race? American Indian or Alaskan Native Native Hawaiian or Other Pacific Islander Asian, Chinese, Japanese, Korean

More information

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice. Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to

More information

Health Risk Assessment

Health Risk Assessment Health Risk Assessment Today s Date: Name Date of Birth GENERAL INFORMATION What is your race? American Indian or Alaskan Native Native Hawaiian or Other Pacific Islander Asian, Chinese, Black/African

More information

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Helping You Manage Your Diabetes

Helping You Manage Your Diabetes CVS Caremark Pharmacy Advisor Program Helping You Manage Your Diabetes Pharmacy Advisor Program Helping You Manage Your Diabetes Contents Know Your Diabetes...4 Medications to Lower Your Risk of Diabetes-Related

More information

Insulin Optimisation Workshop. Theingi Aung & Claire Rowell

Insulin Optimisation Workshop. Theingi Aung & Claire Rowell Insulin Optimisation Workshop Theingi Aung & Claire Rowell Insulin initiation and titration Insulin Preparations Rapid-acting insulin analogues: onset of action of approximately 15 minutes and a duration

More information

Top 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008

Top 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Top 5 (Topics) Papers In GIM 2008 Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Methods Searched ACPJC/EBM, TOC of top medical journals, MEDSCAPE Best Evidence, consultation

More information

OBESITY IN TYPE 2 DIABETES

OBESITY IN TYPE 2 DIABETES OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents

More information

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture.

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. 1 Phar6122: CV section Date: 3/10/05 Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. Directions: This handout includes three chronic heart failure cases of increasing difficulty. In

More information

51 year old woman with hyperglycemia. August 9, 2012 Katie Stanley, MD

51 year old woman with hyperglycemia. August 9, 2012 Katie Stanley, MD 51 year old woman with hyperglycemia August 9, 2012 Katie Stanley, MD HPI Diagnosed with DM 1 year prior to visit Established primary care at that time due to notable weight loss after tobacco cessation

More information

PHYSICIANS INTERACTIVE PARTICIPANT GUIDE

PHYSICIANS INTERACTIVE PARTICIPANT GUIDE PHYSICIANS INTERACTIVE PARTICIPANT GUIDE Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages

More information

The York Diabetes Care Model

The York Diabetes Care Model This Session The York Diabetes Care Model The annual review what s it for and how to do it How to make the diagnosis of diabetes and who to test Categorisation of diabetes at diagnosis Basics of Insulin

More information

Type 2 Diabetes Mellitus Insulin Therapy 2012

Type 2 Diabetes Mellitus Insulin Therapy 2012 Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration

More information

WELL-WOMAN EXAM REVEALS RISK. Katie Jones, MPH, CHES Iowa Department of Public Health Erin Hinderaker, MS, RD, LD Des Moines University

WELL-WOMAN EXAM REVEALS RISK. Katie Jones, MPH, CHES Iowa Department of Public Health Erin Hinderaker, MS, RD, LD Des Moines University WELL-WOMAN EXAM REVEALS RISK Katie Jones, MPH, CHES Iowa Department of Public Health Erin Hinderaker, MS, RD, LD Des Moines University Disclaimer The information provided in this presentation is for informational

More information

Case study: Individual with inadequate glycaemic control due to poor adherence to medication

Case study: Individual with inadequate glycaemic control due to poor adherence to medication Case study: Individual with inadequate glycaemic control due to poor adherence to medication Authored by Linong Ji and Clifford Bailey on behalf of the Global Partnership for Effective Diabetes Management.

More information

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered

More information

More Than Just the Numbers:

More Than Just the Numbers: More Than Just the Numbers: Individualising Patient Care ADEA-QLD Branch Conference 20 April 2018 Case Study 1 Child with Type 1 Diabetes 2 Background and Social History 10 year old female with T1DM since

More information

Insulin Initiation, titration & Insulin switch in the Primary Care-KISS

Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Rotorua GP CME 9 June 2012 Dr Kingsley Nirmalaraj FRACP Endocrinologist, BOPDHB & Suite 9, Promed House, Tenth Ave, Tauranga Linda

More information

Planned Interventions

Planned Interventions Risk Factors Exercise Diabetes Hypertension Tobacco Use Initial Status Patient is currently exercising: More than 150 minutes Less than 150 minutes Per Week Type 1 Type 2 Borderline Diabetic :HgA1c < 6.5%;

More information

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space? Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09

More information

Addressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker:

Addressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker: Addressing Challenges in Type 2 Diabetes Geneva Briggs, PharmD,, BCPS Addressing Challenges in Type 2 Diabetes Speaker: Dr. Geneva Clark Briggs, a board-certified Pharmacotherapy Specialist, received her

More information

Diabetes Self-Management Education Record

Diabetes Self-Management Education Record Diabetes Self-Management Education Record Patient Label Record level of competence and Initial: O=outcomes met; RT=reinforce teaching; NA=not applicable; P=prior knowledge Clinical Outcomes Information

More information

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy

More information

Improving Inpatient Diabetes Care: Focus on Safe Use of Anti-diabetic Therapies

Improving Inpatient Diabetes Care: Focus on Safe Use of Anti-diabetic Therapies Improving Inpatient Diabetes Care: Focus on Safe Use of Anti-diabetic Therapies Leigh Briscoe-Dwyer, PharmD, BCPS, FASHP Chief Pharmacy and Medication Safety Officer North Shore Long Island Jewish Health

More information

Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease

Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease Authored by Paul Zimmet and Richard Nesto on behalf of the Global Partnership for Effective Diabetes Management.

More information

Mixed Insulins Pick Me

Mixed Insulins Pick Me Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing

More information

Subjects are requested to perform self-monitoring of blood glucose (SMBG) 4 times per

Subjects are requested to perform self-monitoring of blood glucose (SMBG) 4 times per APPENDIX 1 Insulin Titration Algorithm Subjects are requested to perform self-monitoring of blood glucose (SMBG) 4 times per day. All subjects will be contacted weekly to review hypoglycemia and adverse

More information

CKD & HT. Anne-Marie Angus

CKD & HT. Anne-Marie Angus CKD & HT Anne-Marie Angus Hypertension definitions Persisting BP >140/90 and HBPM >135/85 Stage 1 >140/90 (HBPM >135/85) Stage 2 >160/100 (HBPM >150/90) Severe >180/100 White coat HT Why treat? A major

More information

IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS

IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes

More information

Diabetes Overview. How Food is Digested

Diabetes Overview. How Food is Digested Diabetes Overview You are The Teacher, The Coach and the Fan Pathophysiology of Diabetes Complications Know the Numbers Treatment Can Good Control Make a Difference? Can Tight Control Be too Tight? How

More information

NEW DIABETES CARE MEDICATIONS

NEW DIABETES CARE MEDICATIONS NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.

More information

APhA March 2016 Annual Meeting Obesity Cases

APhA March 2016 Annual Meeting Obesity Cases APhA March 2016 Annual Meeting Obesity Cases Case #1 Pam is a 47 yo obese Caucasian woman; grade school teacher with a history of HTN, HoTR, and depression who presents for her annual physical. CC: I m

More information

Appendix A: Sample Patient Profiles and Prescriptions

Appendix A: Sample Patient Profiles and Prescriptions Appendix A: Sample Patient Profiles and Prescriptions (For Pharmacist Use) Sample Patient Profile 1 Name Mike Monroe Date of Birth 01/01/1957 Address 555 Happy Lane Phone 123-456-7890 Tucson, AZ 85704

More information

CASES: DIABETES AND PREGNANCY

CASES: DIABETES AND PREGNANCY CASE 1: Visit 1: Ms. Sunny Disposition is a 32 yo G2P1001 who is approximately 15 weeks here for her first prenatal visit. She has already had an US but records not yet received. Pmhx: Unremarkable, no

More information

ROAD TO UNDERSTANDING POLYPHARMACY. Lt Col PHIL L. SAMPLES BS Phr, Pharm. D., BCNSP

ROAD TO UNDERSTANDING POLYPHARMACY. Lt Col PHIL L. SAMPLES BS Phr, Pharm. D., BCNSP ROAD TO UNDERSTANDING POLYPHARMACY Lt Col PHIL L. SAMPLES BS Phr, Pharm. D., BCNSP Definition occurs when: 1. a medical regimen includes at least one unnecessary medication 2. Medications have not been

More information

Endocrinology TeleECHO Clinic Case Presentation Form

Endocrinology TeleECHO Clinic Case Presentation Form Endocrinology TeleECHO Clinic Case Presentation Form Complete ALL ITEMS on this form and fax to 503.228.4801 PLEASE NOTE that case consultations do not create or otherwise establish a provider-patient

More information

Welcome Everyone. Monitoring, Sick Days, Inpatient Management - Objectives. Mrs. Jones has new diabetes. She asks you: Page 1

Welcome Everyone. Monitoring, Sick Days, Inpatient Management - Objectives. Mrs. Jones has new diabetes. She asks you: Page 1 Welcome Everyone Sign-In Enjoy Breakfast Meet someone new Enter Raffle Pick a team name Please silence phones We start at 8:00am Monitoring, Sick Days, Inpatient Management - Objectives Objectives: Strategies

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia Javier Carrasco, MD, PhD Juan Ramón Jiménez Hospital University of Huelva, Spain Case Study: Medical and Social History A 60 years old female

More information

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System

More information

Insulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology

Insulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology Insulin Basics Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology Disclosures Speakers Bureau for Sanofi, Astra Zeneca, Janssen, Boehringer-Ingelheim Objectives Discuss

More information

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for

More information

Journal Club September 29, Vanessa AKIKI PGYlII Internal Medicine

Journal Club September 29, Vanessa AKIKI PGYlII Internal Medicine Journal Club September 29, 2017 Vanessa AKIKI PGYlII Internal Medicine AUBMC 2017 Case Presentation 41-year-old man who was diagnosed with type 1 diabetes 21 years ago presents to your clinic. He believes

More information

Intensification of Diabetic Therapy. Case studies

Intensification of Diabetic Therapy. Case studies Intensification of Diabetic Therapy Case studies Patient #1 1 st visit: 64 year old male, H/O prediabetes, lost weight 280 lbs. to 240 lbs. ER for dental abscess, glucose >300 A1C 11.4%, no diabetic medication,

More information

Sample Exam Questions

Sample Exam Questions Disclaimer These are not validated questions. They have been created to enhance your learning and provide practice in reading and answering multiple choice questions. Some questions have been created to

More information

Management of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE

Management of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE Management of DM in Older Adults: It s not all about sugar! Peggy Odegard, Pharm.D., BCPS, CDE Who needs treatment for DM? 87 year old, frail male with moderately severe dementia living in NH with persistent

More information

Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes!

Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen

More information

MyAction Couple: Primary Prevention Case Study. Teresa Mackay, Rhian Houghton, Tim Grove

MyAction Couple: Primary Prevention Case Study. Teresa Mackay, Rhian Houghton, Tim Grove MyAction Couple: Primary Prevention Case Study Teresa Mackay, Rhian Houghton, Tim Grove Reason for Referral and Patient Demographics Referral Mr Smith Referred by GP High CVD 34.5% QRISK Hypertension (155/92)

More information

Diabetes and the Heart

Diabetes and the Heart Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with

More information

Prediabetes Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Disclosures/Conflict of Interest.

Prediabetes Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Disclosures/Conflict of Interest. Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen

More information

How to Reduce CVD Complications in Diabetes?

How to Reduce CVD Complications in Diabetes? How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year

More information

Long-Term Management Of the ACS Patient: State-of-the-Art. Kim Newlin, CNS, NP-C, FPCNA Sutter Roseville Medical Center Roseville, CA

Long-Term Management Of the ACS Patient: State-of-the-Art. Kim Newlin, CNS, NP-C, FPCNA Sutter Roseville Medical Center Roseville, CA Long-Term Management Of the ACS Patient: State-of-the-Art Kim Newlin, CNS, NP-C, FPCNA Sutter Roseville Medical Center Roseville, CA Disclosures I have no disclosures. Case Study 45 y/o male admitted to

More information

Medicare Wellness. Meggan Robinson, DO MAOFP Spring Update 4/23/16

Medicare Wellness. Meggan Robinson, DO MAOFP Spring Update 4/23/16 Medicare Wellness Meggan Robinson, DO MAOFP Spring Update 4/23/16 Objectives History of Medicare Wellness Exam Identify the goals of the Wellness exam Differentiate the different types of Wellness exams

More information

Type 1 Diabetes Mellitus in the Adult. Katie Davis & Liz DeJulius KNH 411: Medical Nutrition Therapy I

Type 1 Diabetes Mellitus in the Adult. Katie Davis & Liz DeJulius KNH 411: Medical Nutrition Therapy I Type 1 Diabetes Mellitus in the Adult Katie Davis & Liz DeJulius KNH 411: Medical Nutrition Therapy I Diabetes Mellitus: Type I Genetic factor Sudden onset Majority children and adolescents with an increasing

More information

Zetia and Byetta Can Kill (and other recent DM headlines)

Zetia and Byetta Can Kill (and other recent DM headlines) Zetia and Byetta Can Kill (and other recent DM headlines) Jennifer Beach, Pharm.D., CDE UWMC Diabetes Care Center Prandial Percolations Part 4 November 18, 2008: Tacoma ZETIA kills? Data from the Simvastatin

More information

Low HDL-levels: leave it or treat it?

Low HDL-levels: leave it or treat it? Cardiology Update 2011 Davos, 14 02 2011 Low HDL-levels: leave it or treat it? Experts: J.P. Kastelein, Amsterdam and U. Landmesser, Zurich Cases: C. Besler, Zurich and I. Sudano, Zurich Mr H.B., 1960

More information

Case Study: Chris Arden. Peripheral Arterial Disease

Case Study: Chris Arden. Peripheral Arterial Disease Case Study: Chris Arden Peripheral Arterial Disease Patient Presentation Diane is a 65-year-old retired school teacher She complains of left calf pain when walking 50 metres; the pain goes away after she

More information

Welcome to Diabetes MiniSeries Course 2

Welcome to Diabetes MiniSeries Course 2 Welcome to Diabetes MiniSeries Course 2 Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2014, Diabetes Education Services, All Rights Reserved. Diabetes

More information

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

Diabetes Mellitus: Implications of New Clinical Trials and New Medications Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October

More information

Pharmacology Challenges: Managing Statin Myalgia

Pharmacology Challenges: Managing Statin Myalgia Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80

More information

Crossing The Quality Chasm: Cardiovascular Care

Crossing The Quality Chasm: Cardiovascular Care Crossing The Quality Chasm: Cardiovascular Care Philip Madvig, MD Associate Executive Director Partnership for Quality Care Chronic Disease Summit March 19, 2008 The Impact of Cardiovascular Disease In

More information

Controversies in Preventative Cardiology

Controversies in Preventative Cardiology Controversies in Preventative Cardiology Francisco Lopez-Jimenez, M.D., M.Sc, FACC, FAHA Professor of Medicine, Mayo Medical School Chair, Division of Preventive Cardiology Co-Director, Artificial Intelligence

More information

APPENDIX American Diabetes Association. Published online at

APPENDIX American Diabetes Association. Published online at APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no

More information

CURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013

CURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013 CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI

More information

The future is here. It s just not widely distributed yet. William Gibson

The future is here. It s just not widely distributed yet. William Gibson The future is here. It s just not widely distributed yet. William Gibson CHRONIC KIDNEY DISEASE MANAGEMENT A NEW PARADIGM Aaron Cass, MD, FRCPC Nephrologist, Fraser Health January 22, 2014 Where Are We

More information

Diabetes Treatment Update

Diabetes Treatment Update Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers

More information

Pharmacy Partnership to Improve Patient Outcomes

Pharmacy Partnership to Improve Patient Outcomes Pharmacy Partnership to Improve Patient Outcomes Minnesota Rural Health Conference Session 2B Ryan M. Harden, MD MS Kendra Metz, Pharm D Sarah Nelson, MD June 25, 2018 Involved Partners Involved Partners

More information

Developed by the Hannibal Regional Hospital Diabetes and Wound Ostomy Center as part of the Better Self Management of Diabetes program, funded by the

Developed by the Hannibal Regional Hospital Diabetes and Wound Ostomy Center as part of the Better Self Management of Diabetes program, funded by the Developed by the Hannibal Regional Hospital Diabetes and Wound Ostomy Center as part of the Better Self Management of Diabetes program, funded by the Missouri Foundation for Health. BSMOD Organizational

More information

DIABETES Self Directed Test (12 Hours) Name: Ward/Practice Area: Mailing Address:

DIABETES Self Directed Test (12 Hours) Name: Ward/Practice Area: Mailing Address: 1 DIABETES Self Directed Test (12 Hours) Name: Ward/Practice Area: Mailing Address: 2 Learning Outcomes All nurses, regardless of practice setting, are required to work collaboratively with the person

More information

Comprehensive Diabetes Treatment

Comprehensive Diabetes Treatment Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes

More information

Objectives. Kidney Complications With Diabetes. Case 10/21/2015

Objectives. Kidney Complications With Diabetes. Case 10/21/2015 Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information